Genmab gained the payment from GlaxoSmithKline which was triggered by the NDA submission of Arzerra.
The application seeks approval for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received prior therapy.
According to Genmab, the announcement does not affect its financial guidance for 2012.
Genmab is a publicly traded company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer.